Life Science Nation Newsletter | November 19, 2015 | Issue 138
|
|
 Life Science Investor Mandates (Nov 12 - Nov. 18) |
| |
|
Investing in Healthcare IT, Diagnostics and Medical Devices
|
Investing in Therapeutics
|
|
Seeking Early Stage Therapeutics and Devices
|
|
Seeking MedTech Innovations Globally
|
|
Pitching to a Foundation? Be Prepared for These Issues
|
Regulation A+: What Life Science CEOs Need to Know
|
RESI Panel Announcement: Venture Philanthropy Investors
|
|
|
|
Earlier this year, we offered an in-depth exploration of foundations that provide funding to startup companies. Many foundations and patient groups are now interested in working with startup companies to fund projects that further their mission, and while many life science companies could benefit from approaching foundations for funding, there are certain criteria that foundations typically have to follow in order to bring their support for startup companies in line with their broader mission.
While each foundation is unique, here are a few criteria that we've repeatedly seen raised by foundations. If you're pitching to a foundation for funding, you may wish to keep the following considerations in mind...
|
 |
|
|
Keeping up with the trends and changes of the investor landscape is no easy task. For fundraising companies, however, being familiar with the rules and regulations of raising capital is an important component of the process. On March 25, 2015, the Securities and Exchange Commission adopted a significant amendment to Regulation A in accordance with Section 401(a) of the JOBS Act. Having been largely ignored by most fundraising companies, with these changes Regulation A could become a viable alternative for those who can't meet the costs or size requirements of an IPO.
Here's what you need to know about the updated law.
Previously, fundraising companies could raise no more than $5 million in a 12-month period and were forced to comply with each individual state's "blue sky laws...
|
|
|
|
Venture philanthropy has been a vital source of capital for early stage life science companies over the years. Philanthropic organizations provide more than just financing; a foundation with a niche indication focus may supply a network of experts, patients, and resources in the field. These organizations have an underlying mission to improve specific patient outcomes, going as far as using their financial returns toward further initiatives and investments to achieve their mission. Due to these organizations' unique missions, LSN has uncovered a number of investment trends and accumulated advice in how to approach venture philanthropy investors.
LSN is pleased to announce a panel of five expert representatives in the venture philanthropy space for the RESI San Francisco Conference on January 12th. Moderated by Chris de Souza, Director of Broadview Ventures, the panel will be joined by:
- Lindy Fishburne, Executive Director, Thiel Foundation & Breakout Labs
- Rachel Rimsky, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research
- Daniel Smith, VP of Innovative Technologies, Autism Speaks
- Patricia Zilliox, Chief Drug Development Officer, Foundation Fighting Blindness
|
 |
|
|
|
|
|
|
|
|
